Quapat 0.2% Eye Drop
Marketer
Raymed Pharmaceuticals Ltd
Composition
Olopatadine (0.2% W/V)
About Quapat 0.2% Eye Drop
Quapat 0.2% Eye Drop (Olopatadine) is an antihistamine eye drop used to relieve the symptoms of allergic conjunctivitis. Common side effects include burning, stinging, and eye irritation. It is important to follow your doctor's instructions carefully and do not exceed the recommended dosage. Consult your doctor before using olopatadine if you are pregnant, breastfeeding, or have any underlying medical conditions.
Frequently Asked Questions (FAQs)
How long does it take for Quapat 0.2% Eye Drop (Olopatadine) to work?
Can I use Quapat 0.2% Eye Drop (Olopatadine) if I wear contact lenses?
What should I do if I miss a dose of Quapat 0.2% Eye Drop (Olopatadine)?
What should I do if I accidentally use too much Quapat 0.2% Eye Drop (Olopatadine)?
Last Updated On 04 Jul. 2025 | 03:25 PM (IST)
Report Error
Was this Product Information helpful?
Some people found this information helpful
User Feedback
Disclaimer
We, at MedCart make a diligent attempt to deliver accurate, expert-drafted and thoroughly reviewed
medicine-related information to our consumers. However, it should, by no means, be considered a
substitute for a prescription from a certified doctor or a trustworthy doctor-patient relationship.
In fact, we detest any form of self-medication without expert advice. The sole purpose of the
information on our portal is to educate our consumers, which helps improve the communication
between a doctor and a patient. The information by no means is complete in its entirety and
should not be used to diagnose or treat any medical condition. No amount of information can
replace the experience and expertise of a doctor, therefore his/her advice always holds
priority and should be followed appropriately.
5k+ people saw this product recently
MRP
₹200.00
In Stock
₹200.00
For Churna (s)
Inclusive of all Taxes
Delivery Pincode
Check
Delivery in 60-90 mins
Cash on Delivery Available
Easy 7 Days Return Available
Expires on or after Dec 2024
Country of Origin: India
User Feedback